Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (10)

2021

  1. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)

    Actas Urologicas Espanolas, Vol. 45, Núm. 2, pp. 93-102

2018

  1. Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo

    Actas Urologicas Espanolas

2015

  1. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013

    European Urology, Vol. 68, Núm. 2, pp. 256-262

  2. Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial

    European Urology, Vol. 67, Núm. 3, pp. 508-516

2013

  1. A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness

    PLoS ONE, Vol. 8, Núm. 1

2011

  1. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    European Urology, Vol. 60, Núm. 3, pp. 423-430

2009

  1. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

    Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203

2008

  1. Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

    European Urology, Vol. 53, Núm. 5, pp. 992-1002

2007

  1. A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

    European Urology, Vol. 52, Núm. 5, pp. 1398-1406

2005

  1. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

    Journal of Urology, Vol. 174, Núm. 4 I, pp. 1242-1247